Related references
Note: Only part of the references are listed.Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
The Cross-Validated Adaptive Signature Design
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2010)
Predictive biomarker validation in practice: lessons from real trials
Sumithra J. Mandrekar et al.
CLINICAL TRIALS (2010)
The efficiency of clinical trial designs for predictive biomarker validation
K. Y. Young et al.
CLINICAL TRIALS (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Biomarkers and surrogate end points-the challenge of statistical validation
Marc Buyse et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effective Incorporation of Biomarkers into Phase II Trials
Lisa M. McShane et al.
CLINICAL CANCER RESEARCH (2009)
Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Sumithra J. Mandrekar et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer.
Sanford D. Markowitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Overview of Colorectal Cancer Genetics
Robert Gryfe
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Genomic advances and their impact on clinical trial design
Sumithra J. Mandrekar et al.
GENOME MEDICINE (2009)
Randomized phase III clinical trial designs for targeted agents
Antje Hoering et al.
CLINICAL CANCER RESEARCH (2008)
Utilization of genomic signatures to direct use of primary chemotherapy
Anil Potti et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical application of the 70-gene profile: The MINDACT trial
Fatima Cardoso et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Development and validation of biomarker classifiers for treatment selection
Richard Simon
JOURNAL OF STATISTICAL PLANNING AND INFERENCE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect
Wenyu Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Sue-Jane Wang et al.
PHARMACEUTICAL STATISTICS (2007)
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
E. A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
B Freidlin et al.
CLINICAL CANCER RESEARCH (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Clinical trial designs for prospective validation of biomarkers
SJ Mandrekar et al.
AMERICAN JOURNAL OF PHARMACOGENOMICS (2005)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Issues in clinical trial design for tumor marker studies
D Sargent et al.
SEMINARS IN ONCOLOGY (2002)
Share Paper
